Market Competition in Aid of Humanitarian Concern: Reconsidering Pharmaceutical Drug Patents
Bibliographic record
Abstract
The grant of monopoly patent protection isjustified normally as a means for giving incentive for innovation.Market-driven innovation is not necessarily equitable, however, and the development concerns over the international intellectual property regime governing the products of medical research are particularly pressing given the basic necessities involved.The market patent system may be said to fail individuals in developing countries in regards to both focus and access, as no incentive is given for research into maladies not present in wealthy marketplaces; or even if a medicine is universally required, then access is precluded economically from the poor.The following paper considers recently popular prize fund alternatives to the patent system, and arrives at a new alternative that is based upon market reward and the retention of patentability.The proposal offered attempts to incorporate global health measures into a competitive system of tradable patent terms.Under this proposal pharmaceutical advances which serve a humanitarian purpose would receive a patent term that is severable from the originating idea or formula, so as to become a free-floating and tradable patent term.Discoveries of humanitarian medicines, or their donation, may in this manner achieve market value through the trade and application of the floating protection term to another, more commercially viable pharmaceutical product.Ideally, this proposal would serve to equate advances of a humanitarian and non-market nature with the most lucrative market drugs, and to further have blockbuster drug sales indirectly finance humanitarian advances.Intro du ction ......
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.018 | 0.023 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.002 | 0.001 |
| Science and technology studies | 0.006 | 0.034 |
| Scholarly communication | 0.018 | 0.019 |
| Open science | 0.002 | 0.007 |
| Research integrity | 0.021 | 0.011 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".